Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale ...

Ianalumab acts against B cells, white blood cells in the immune system, when they overreact and mistakenly attack the patient's own body. By blocking signals that these B cells need to grow and ...

The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia were able to maintain safe ...

Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...

Ouro Medicines’ BCMAxCD3 T cell engager antibody candidate, gamgertamig gets US FDA orphan drug designation to treat immune thrombocytopenia: South San Francisco Tuesday, Decemb ...

Key Takeaways An experimental drug can help many with a rare autoimmune bleeding conditionMore than half of people with immune thrombocytopenia wound up with healthy platelet levels after treatment ...